Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash from Operations (2020 - 2025)

Oncology Institute (TOI) has disclosed Cash from Operations for 6 consecutive years, with 12630000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 1642.12% year-over-year to 12630000.0, compared with a TTM value of 23634000.0 through Sep 2025, up 31.73%, and an annual FY2024 reading of 26538000.0, up 26.92% over the prior year.
  • Cash from Operations was 12630000.0 for Q3 2025 at Oncology Institute, down from 10202000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 4186000.0 in Q4 2024 and bottomed at 23335000.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 9742578.95, with a median of 10202000.0 recorded in 2025.
  • The sharpest move saw Cash from Operations skyrocketed 1713.91% in 2021, then crashed 3759.7% in 2022.
  • Year by year, Cash from Operations stood at 23335000.0 in 2021, then surged by 40.02% to 13997000.0 in 2022, then soared by 72.19% to 3893000.0 in 2023, then surged by 207.53% to 4186000.0 in 2024, then plummeted by 401.72% to 12630000.0 in 2025.
  • Business Quant data shows Cash from Operations for TOI at 12630000.0 in Q3 2025, 10202000.0 in Q2 2025, and 4988000.0 in Q1 2025.